BeiGene, Ltd. (HKG:6160)

Market Cap	196.20B
Revenue (ttm)	32.49B
Net Income (ttm)	-3.05B
Shares Out	n/a
EPS (ttm)	-28.81
PE Ratio	n/a
Forward PE	74.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,086,052
Average Volume	7,015,322
Open	133.00
Previous Close	140.40
Day's Range	125.10 - 134.00
52-Week Range	85.00 - 178.00
Beta	0.35
RSI	35.81
Earnings Date	May 14, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD